Randomized trial shows AD109 significantly improves sleep apnea symptoms in adults — Evidence Review

A large phase 3 trial found that a once-nightly oral medication (AD109) significantly reduced obstructive sleep apnea (OSA) severity in adults who could not tolerate CPAP, offering a promising alternative. Related studies broadly support these findings, showing consistent efficacy and safety of AD109 and similar drug combinations.

• Multiple randomized controlled trials have demonstrated that AD109—combining aroxybutynin and atomoxetine—reduces apnea-hypopnea index (AHI) and hypoxic burden, with improvements often greater than those seen with placebo and similar across different OSA severities 1 2 3 5.
• Meta-analyses and mechanistic trials indicate that pharmacological approaches targeting neuromuscular dysfunction (as with AD109) yield modest but clinically meaningful reductions in OSA severity, particularly among male and less obese patients 4 6 9.
• Although CPAP remains the gold standard, these studies reinforce the potential of pharmacotherapy as an adjunct or alternative for patients who are unable or unwilling to use CPAP 9 10 11.

Study Overview and Key Findings

Obstructive sleep apnea (OSA) affects millions worldwide, but the standard therapy—continuous positive airway pressure (CPAP)—is often poorly tolerated, leaving many patients untreated. The new phase 3 SynAIRgy trial assesses the efficacy of AD109, a once-nightly oral medication that targets the neuromuscular causes of airway collapse, addressing a major gap in OSA management. Conducted among adults unable or unwilling to use CPAP, the study provides important evidence for a pharmacological approach to OSA, a field where few effective drug therapies exist.

Property	Value
Study Year	2026
Organization	University of Pittsburgh Medical Center
Journal Name	American Journal of Respiratory and Critical Care Medicine
Authors	Patrick J Strollo, Ron Farkas, Luigi Taranto-Montemurro, John Cronin, Sanjay R Patel, SynAIRgy Investigators, Akinyemi Ajayi, Bernadette Alejandrino, Jerome Alonso, Najib Ayas, Francisco Badar, Jacob Coleman, William Cooper, Bruce Corser, Ronald Cridland, Dominick D’Aunno, Matthew Davis, Bertrand De Silva, Michael Downing, Alaa El-Gendy, Tomas Fiel, Steven Geller, James Geyer, Andrew Gould, Nella Green, Mario Guillen, John Hemmersmeier, John Hudson, Monica Jaffe, Thomas Jarrett, John Khoury, John Kimoff, Oleg Kouskov, Michael Lacey, Judith Leech, David Lesch, Michael Lillestol, Reinero Linares – Mera, Alan Lowe, Kinjal Madhav, David Marks, Ronald Mayfield, James Maynard, Jessica McCoun, Tatyana Miroshnikova, Rizwana Mohseni, Andrew Pastewski, Paresh Patel, Sanjay Patel*, Susheel Patil, Nirupa Paulraj, Enrique Pelayo, Dena Petersen, Alec Platt, Lew Pliamm, Bruce Rankin, Syed Raza, Anne Romaker, Mark Rosenthal, Eugene Ryan, Hector Sanchez, Andrew Schreiber, Sonja Schuetz, Sudhir Sehgal, Colin Shapiro, Craig Shapiro, Gerald Shockey, Hermandeep Singh, Sushil Singhi, Steve Sitar, Eileen Sloan, Damien Stevens, Kenneth Stiel, Patrick J Strollo, Masayoshi Takashima, Stephen Thein, Patrick Whitten, Paul Wylie, Dragos Zanchi
Population	Adults with mild to severe obstructive sleep apnea
Sample Size	646 adults
Methods	Randomized Controlled Trial (RCT)
Outcome	Breathing interruptions, oxygen deprivation, overall blood oxygen levels
Results	AD109 reduced apnea-hypoxia index by 44%, placebo by 18%

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus research database, which contains over 200 million papers. We used the following queries to locate relevant studies:

1. AD109 sleep apnea treatment efficacy
2. apnea-hypoxia index reduction medications
3. placebo effects sleep apnea trials

Below is a summary of key topics and findings from related studies:

Topic	Key Findings
How effective are AD109 and similar drug combinations in reducing OSA severity?	- AD109 significantly reduces AHI and hypoxic burden compared to placebo in both phase 2 and phase 3 trials 1 2 3 5. - The efficacy is generally consistent across mild to severe OSA, with some evidence of greater responsiveness in patients with lower BMI 4.
What are the safety and tolerability profiles of these pharmacological treatments?	- AD109 and similar combinations demonstrate mostly mild, expected side effects (dry mouth, insomnia, urinary hesitancy), with discontinuation rates due to side effects in the range of 20% 1 2 3. - Safety profiles are favorable compared to CPAP non-adherence, but long-term safety data are limited 1 2 5.
How does pharmacotherapy compare to CPAP in efficacy and patient adherence?	- CPAP remains the gold standard and provides robust improvements in OSA symptoms and daytime function when tolerated, but pharmacotherapy offers a meaningful alternative for those unable to adhere to CPAP 9 10 11. - Drug treatments are less effective than optimal CPAP but may fill a gap for undertreated patients 9.
What patient factors predict better or worse response to AD109 and similar medications?	- Patients with lower BMI and more severe sleep apnea symptoms at baseline tend to have better responses to AD109 4. - Males may experience greater reductions in AHI from pharmacological interventions 9.

How effective are AD109 and similar drug combinations in reducing OSA severity?

The new phase 3 trial aligns with prior studies, showing that AD109 produces substantial reductions in AHI and hypoxic burden, with a notable proportion of patients achieving clinically meaningful improvements. Earlier phase 2 trials and smaller studies reported similar efficacy, supporting the robustness of these findings across different study designs and populations.

• Phase 2 and phase 3 trials consistently demonstrate a 40-47% reduction in AHI with AD109, compared to much smaller reductions with placebo 1 2 3 5.
• Improvements are seen across mild, moderate, and severe OSA cases, broadening the potential applicability of AD109 3 5.
• Earlier studies using combinations of atomoxetine and oxybutynin also reported substantial reductions in OSA severity, validating the neuromuscular-targeted pharmacological approach 6.
• Meta-analyses confirm a modest but significant reduction in OSA severity with combined noradrenergic and antimuscarinic agents, supporting the clinical utility of AD109 9.

What are the safety and tolerability profiles of these pharmacological treatments?

Most studies report that AD109 and similar combinations are generally well tolerated, with side effects that are mostly mild and predictable. While up to one-fifth of participants discontinued due to adverse effects, this is comparable to or better than dropout rates seen with CPAP in real-world practice.

• Common side effects include dry mouth, insomnia, and urinary hesitancy, with few serious adverse events reported 1 2 3.
• Phase 2 and 3 trials found discontinuation rates due to side effects in the range of 15-21% 1 2 3.
• Longer-term safety data are still needed to fully assess the risk-benefit profile, especially with chronic nightly use 1 2 5.
• The safety profile may be more favorable than ongoing untreated OSA, which carries significant cardiovascular and metabolic risks 1 5.

How does pharmacotherapy compare to CPAP in efficacy and patient adherence?

CPAP remains the most effective treatment for OSA in terms of symptom relief and improvement in daytime functioning. However, pharmacotherapy like AD109 may offer a practical alternative for patients who are unwilling or unable to adhere to CPAP, potentially increasing overall treatment rates in the OSA population.

• CPAP provides greater improvements in AHI and quality of life when used as prescribed, but adherence is often poor, leaving many patients untreated 10 11.
• Pharmacological treatments such as AD109 are less effective than optimal CPAP but can meaningfully reduce disease severity and symptoms, especially for patients not using CPAP 9.
• Combination approaches or stepwise strategies may be beneficial, with pharmacotherapy used as an adjunct or fallback for non-adherent patients 9 11.
• The new phase 3 trial specifically targeted patients not using CPAP, highlighting the real-world relevance of pharmacotherapy for this subgroup 1.

What patient factors predict better or worse response to AD109 and similar medications?

Emerging evidence suggests that certain patient characteristics, such as lower BMI and greater symptom burden, predict better responses to AD109. This highlights the importance of individualized therapy and may help guide patient selection in clinical practice.

• Lower baseline BMI is associated with a greater likelihood of achieving a ≥50% reduction in AHI with AD109 4.
• Patients with more severe subjective symptoms (fatigue, sleep impairment) may also experience greater benefit from pharmacotherapy 4.
• Males appear to have a greater reduction in AHI with combined noradrenergic/antimuscarinic agents, based on meta-regression analyses 9.
• These findings may inform future precision medicine approaches to OSA treatment and the design of future clinical trials 4 9.

Future Research Questions

While the phase 3 trial provides strong evidence for the short-term efficacy and safety of AD109, several important questions remain. Future research is needed to clarify long-term outcomes, optimize patient selection, and explore combination or adjunctive treatment strategies to reduce the burden of untreated OSA.

Research Question	Relevance
What are the long-term safety and efficacy outcomes of AD109 in OSA patients?	The current data are limited to 6-month follow-up; longer-term studies are needed to assess sustained efficacy, ongoing safety, and potential rare adverse events 1 2.
Which patient subgroups benefit most from AD109 treatment?	Identifying predictors of response (e.g., BMI, sex, symptom burden) could enable personalized therapy and optimized patient selection 4 9.
How does AD109 compare with CPAP and other OSA therapies in head-to-head trials?	Direct comparison studies would clarify relative efficacy, adherence, and patient preference, informing clinical guidelines and patient counseling 9 10 11.
Can AD109 effectively be used in combination with other OSA interventions (e.g. weight loss, oral appliances)?	Many patients require multimodal management; studying combined approaches could improve outcomes for those with partial responses to single therapies 8 12.
What is the impact of AD109 on cardiovascular and metabolic risk factors in OSA patients?	OSA is associated with increased cardiovascular risk; assessing whether AD109 improves long-term cardiometabolic outcomes is essential for understanding its full clinical value 1 12.

---

This article provides a comprehensive, evidence-based summary of the latest findings on AD109 for obstructive sleep apnea, as well as context from the broader research literature.